Fountain Nathan B
SEC Form 4 insider trading activity
Fountain Nathan B has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 10, 2026.
On the most recent filing, Fountain Nathan B is listed as Director at Acumen Pharmaceuticals, Inc. Inside the rolling window, Fountain Nathan B reported no open-market purchases and 1 open-market sale totaling $14K in ABOS.
Companies traded
Other insiders at ABOS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$14K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Fountain Nathan B made?
Fountain Nathan B has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Fountain Nathan B trade?
Fountain Nathan B has filed SEC Form 4 disclosures for 1 company, including ABOS.
When was Fountain Nathan B's most recent SEC Form 4 filing?
Fountain Nathan B's most recent SEC Form 4 filing on Tracefour is dated Jun 10, 2026.
What is Fountain Nathan B's total buy and sell value in the current window?
Inside the rolling retention window, Fountain Nathan B bought $0 and sold $14K based on SEC Form 4 filings.
What was Fountain Nathan B's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,400 ABOS shares on 2026-06-09, worth $14K, per SEC Form 4 filings.